7 completed, 3 recruiting. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Recruiting 3 |
| Phase 2 | 1 | Recruiting 1 |
Follow trospium chloride: new trials by email Literature Review of trospium chloride trials Research Report on trospium chloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia Xanomeline and trospium chloride (KarXT) - SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder | Phase 1 / Phase 2 | Recruiting | New York State Psychiatric Institute | 12 | 2026-07-01 | 2026-07-14 |
| A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants Xanomeline/ Trospium Chloride - Healthy Volunteers | Phase 1 | Recruiting | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 56 | 2025-10-13 | 2026-10-13 |
| A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin KarXT, Midazolam, Fexofenadine - Healthy Volunteers | Phase 1 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 62 | 2025-09-29 | 2026-07-22 |
| A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Trospium Chloride - Healthy Volunteers | Phase 1 | Recruiting | Bristol-Myers Squibb | 236 | 2025-06-27 | 2026-08-17 |
| Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders KarXT, KarX-EC - Psychiatric Disorders | Phase 1 | Completed | Bristol-Myers Squibb | 24 | 2025-04-29 | 2025-08-06 |
| A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants Xanomeline/Trospium Chloride, Lithium, Valproic Acid - Healthy Volunteers | Phase 1 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 133 | 2024-12-26 | 2026-02-24 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants KarXT, KarX-EC, Placebo - Healthy Volunteers | Phase 1 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 78 | 2024-10-01 | 2025-07-04 |
| Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1 intravenous infusion of 2 mg trospium chloride, oral administration of 30 mg trospium chloride, oral administration of 300 mg ranitidine - Pharmacokinetics, Inhibition Enzyme | Phase 1 | Completed | Dr. R. Pfleger Chemische Fabrik GmbH | 24 | 2016-11-01 | 2017-04-10 |
| Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium xanomeline tartrate, Trospium chloride - Schizophrenia | Phase 1 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 70 | 2016-09-07 | 2017-04-19 |
| Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects Trospium Chloride (Sanctura XR®), Metformin hydrochloride (Glucophage®) - Healthy | Phase 1 | Completed | Allergan | 44 | 2009-10-01 | 2011-12-19 |
Mental Disorders (1) · Schizophrenia (1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company (5) · Bristol-Myers Squibb (2) · Allergan (1) · Dr. R. Pfleger Chemische Fabrik GmbH (1) · New York State Psychiatric Institute (1)
United States (8) · United Kingdom (1)
Joshua T Kantrowitz, MD (1) · Lukasz Biernat, PhD (1) · Ragy Girgis, MD (1)